Empower Advisory Group LLC Has $717,000 Position in Stryker Co. (NYSE:SYK)

Empower Advisory Group LLC increased its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 52.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,991 shares of the medical technology company's stock after purchasing an additional 684 shares during the period. Empower Advisory Group LLC's holdings in Stryker were worth $717,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp grew its position in Stryker by 2.2% in the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock worth $5,279,788,000 after buying an additional 316,404 shares during the last quarter. FMR LLC grew its position in Stryker by 3.0% in the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock worth $2,639,725,000 after buying an additional 215,782 shares during the last quarter. Geode Capital Management LLC grew its position in Stryker by 2.5% in the third quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company's stock worth $2,484,893,000 after buying an additional 165,490 shares during the last quarter. Parnassus Investments LLC acquired a new position in Stryker in the third quarter worth approximately $762,798,000. Finally, Janus Henderson Group PLC grew its position in Stryker by 1.5% in the third quarter. Janus Henderson Group PLC now owns 1,969,757 shares of the medical technology company's stock worth $711,594,000 after buying an additional 28,421 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

Stryker stock traded down $3.82 on Friday, reaching $382.59. 1,268,413 shares of the stock were exchanged, compared to its average volume of 1,388,856. The stock has a market cap of $145.99 billion, a PE ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a fifty day moving average price of $377.92 and a two-hundred day moving average price of $368.21.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business posted $3.46 EPS. Sell-side analysts anticipate that Stryker Co. will post 13.49 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's payout ratio is currently 43.30%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SYK. BTIG Research lifted their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Canaccord Genuity Group lifted their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Wells Fargo & Company lifted their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. UBS Group lifted their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Stryker has a consensus rating of "Moderate Buy" and an average price target of $420.68.

Insider Activity at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.